Natco Pharma’s API plant in Hyderabad gets U.S. FDA observation


Generic drugmaker Natco Pharma’s active pharmaceutical igredients (API) manufacturing plant in Mekaguda, Hyderabad, has been issued a Form 483 with one observation by the U.S. Food and Drug Administration. The U.S. FDA conducted the inspection from June 9-13, and on conclusion, the company received one observation in the Form-483. The company believes it is procedural in nature and is confident to address the observation comprehensively, Natco Pharma said in a filing on Friday.

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *